Progyny (PGNY) to Release Earnings on Thursday

Key Points

• Progyny is set to announce its Q2 2025 earnings on August 7th, with expected earnings of $0.42 per share and revenue of $315.70 million.
• The company recently reported earnings of $0.17 per share for the previous quarter, missing estimates, but showed a 16.5% year-over-year revenue increase.
• Analysts have varied ratings on Progyny, with some upgrades to "buy" and target prices ranging from $21.00 to $28.00, leading to an average consensus target price of $24.82.

Progyny (NASDAQ:PGNY - Get Free Report) is expected to be posting its Q2 2025 quarterly earnings results after the market closes on Thursday, August 7th. Analysts expect Progyny to post earnings of $0.42 per share and revenue of $315.70 million for the quarter. Progyny has set its Q2 2025 guidance at 0.400-0.430 EPS and its FY 2025 guidance at 1.540-1.640 EPS.

Progyny (NASDAQ:PGNY - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.45 by ($0.28). The business had revenue of $324.04 million for the quarter, compared to analyst estimates of $307.86 million. Progyny had a net margin of 4.33% and a return on equity of 10.90%. The company's quarterly revenue was up 16.5% on a year-over-year basis. During the same period in the prior year, the company earned $0.17 earnings per share. On average, analysts expect Progyny to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Progyny Price Performance

NASDAQ PGNY traded down $1.02 during trading on Friday, hitting $22.49. The company's stock had a trading volume of 1,210,981 shares, compared to its average volume of 1,006,189. Progyny has a fifty-two week low of $13.39 and a fifty-two week high of $27.15. The company has a market cap of $1.93 billion, a PE ratio of 39.46, a P/E/G ratio of 2.26 and a beta of 1.32. The business's 50 day simple moving average is $22.11 and its 200-day simple moving average is $22.11.

Insiders Place Their Bets

In other news, Director Cheryl Scott sold 2,675 shares of the stock in a transaction dated Wednesday, June 11th. The shares were sold at an average price of $22.07, for a total transaction of $59,037.25. Following the sale, the director directly owned 14,112 shares of the company's stock, valued at $311,451.84. This represents a 15.93% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 9.40% of the company's stock.

Hedge Funds Weigh In On Progyny

A number of large investors have recently bought and sold shares of the business. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in Progyny by 6.0% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 252,032 shares of the company's stock worth $5,630,000 after acquiring an additional 14,297 shares during the period. Amundi grew its position in shares of Progyny by 103.8% in the first quarter. Amundi now owns 11,419 shares of the company's stock valued at $264,000 after purchasing an additional 5,817 shares during the period. Finally, Royal Bank of Canada increased its stake in shares of Progyny by 384.8% during the first quarter. Royal Bank of Canada now owns 13,027 shares of the company's stock worth $291,000 after purchasing an additional 10,340 shares in the last quarter. Institutional investors and hedge funds own 94.93% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms recently commented on PGNY. Leerink Partners upgraded shares of Progyny from a "market perform" rating to an "outperform" rating and set a $28.00 target price for the company in a research note on Tuesday, July 8th. Wall Street Zen upgraded shares of Progyny from a "hold" rating to a "buy" rating in a research note on Saturday, July 26th. Canaccord Genuity Group cut their target price on Progyny from $23.00 to $21.00 and set a "hold" rating on the stock in a research report on Monday, May 12th. Leerink Partnrs raised Progyny from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, July 8th. Finally, Truist Financial increased their price objective on Progyny from $24.00 to $27.00 and gave the company a "hold" rating in a report on Thursday, July 17th. Five research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Progyny currently has a consensus rating of "Moderate Buy" and an average price target of $24.82.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.